Ocular Therapeutix, Inc.
OCUL
$10.04
-$0.06-0.59%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | 24.94% | -18.60% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 24.94% | -18.60% | |||
| Cost of Revenue | -16.87% | 28.91% | |||
| Gross Profit | 24.81% | -45.00% | |||
| SG&A Expenses | 7.80% | 19.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -8.20% | 25.44% | |||
| Operating Income | 12.03% | -33.80% | |||
| Income Before Tax | 11.11% | -37.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 11.11% | -37.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 11.11% | -37.06% | |||
| EBIT | 12.03% | -33.80% | |||
| EBITDA | 12.82% | -34.36% | |||
| EPS Basic | 11.46% | -36.34% | |||
| Normalized Basic EPS | 11.45% | -36.37% | |||
| EPS Diluted | 12.48% | -37.93% | |||
| Normalized Diluted EPS | 11.45% | -36.37% | |||
| Average Basic Shares Outstanding | 0.38% | 0.53% | |||
| Average Diluted Shares Outstanding | 0.38% | 0.53% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||